The triple-negative breast cancer (TNBC), which accounts for 10–20% of all breast malignancies, is characterized by the absence of the estrogen receptor (ER) and the progesterone receptor (PR) without the amplification of the human epidermal growth factor receptor 2 (HER2) [1]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.